https://www.onivyde.com/en-us/hcp 2025-12-12T05:13:13+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients 2025-12-19T10:52:21+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/learn-about-onivyde/starting-treatment 2024-04-03T06:09:44+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/learn-about-onivyde/how-onivyde-works 2024-04-03T06:12:19+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/learn-about-onivyde/how-onivyde-is-given 2024-04-03T07:00:25+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/understanding-side-effects/side-effects 2024-04-03T06:25:58+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/understanding-side-effects/tips-to-manage-diarrhea 2025-09-25T04:56:43+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/support-and-resources/ipsen-cares 2025-09-30T05:08:06+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/support-and-resources/patient-resources 2025-12-19T12:39:32+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/treatment-information/how-onivyde-works/liposomal-technology 2025-12-12T05:23:21+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/nccn-recommendation-irinotecan 2025-12-12T05:34:27+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/clinical-evidence/primary-efficacy-analysis 2024-03-06T08:15:19+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/clinical-evidence/napoli-1-study-design 2024-05-30T06:22:00+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/first-line-napoli-3/safety-data 2025-12-12T05:50:28+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/first-line-napoli-3/recommended-dosing 2025-12-12T05:53:16+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/first-line-napoli-3/dosing-modifications 2025-12-12T05:55:09+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/managing-adverse-reactions 2022-08-26T06:34:20+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/support-and-resources/ipsen-cares 2025-12-24T12:35:23+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/support-and-resources/resource-library 2025-12-23T17:03:00+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/support-and-resources/videos 2024-07-22T11:17:18+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/support-and-resources/contact-ipsen 2025-12-12T06:22:00+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/treatment-information/how-onivyde-works/pharmacokinetics 2024-03-06T08:17:40+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/clinical-evidence/first-line-napoli-3/efficacy 2025-12-12T05:38:36+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/post-gemcitabine-napoli-1/safety-data 2025-12-12T05:58:52+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/post-gemcitabine-napoli-1/recommended-dosing 2025-12-12T06:10:07+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/safety-and-dosing/post-gemcitabine-napoli-1/dosing-modifications 2025-12-12T06:12:03+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/clinical-evidence/post-gemcitabine-napoli-1/study-design 2025-12-12T05:46:36+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/clinical-evidence/post-gemcitabine-napoli-1/efficacy 2025-12-22T09:51:07+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/clinical-evidence/first-line-napoli-3/study-design 2025-10-28T12:30:51+00:00 weekly 1.0 https://www.onivyde.com/en-us/hcp/site-map 2025-12-23T04:56:54+00:00 weekly 1.0 https://www.onivyde.com/en-us/for-patients/site-map 2025-12-19T11:11:58+00:00 weekly 1.0